What Has Been the Growth Trajectory for the Duchenne Muscular Dystrophy Market in Recent Years?
The duchenne muscular dystrophy market has seen considerable growth due to a variety of factors.
• The market for Duchenne muscular dystrophy has seen robust expansion in the last few years. An increase from $1.16 billion in 2024 to $1.26 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.9% is predicted. The growth during this historic period is a result of factors such as advanced genetic comprehension and diagnostics, progress in clinical trials, patient activism and awareness, special status and incentives for orphan drugs, and initiatives for collective research.
What Are the Future Growth Projections for the Duchenne Muscular Dystrophy Market?
The duchenne muscular dystrophy market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for Duchenne muscular dystrophy is projected to experience robust expansion in the subsequent few years. It is set to reach $1.75 billion by 2029, with a compound annual growth rate (CAGR) of 8.5%.
The predicted growth within this period can be tied to the rise of gene therapies, precision medicine strategies, broader therapy access, enduring follow-up studies, and advancements in regulations. Key trends for the forecast period involve the incorporation of digital health technologies, improvements in therapeutics technology, gene therapies, and genetic medicines, regulatory backing for rare disease drugs, and precision medicine tactics.
What Factors Are Driving Growth In The Duchenne Muscular Dystrophy Market?
The escalating occurrence of lasting health conditions is projected to trigger the expansion of the Duchenne muscular dystrophy market in the years to come. Long-term health issues or conditions that persist for over a year are termed as chronic illness. The Duchenne muscular dystrophy plays a part in the occurrence of such diseases by catering to the specific medical needs of individuals suffering from this genetic anomaly, thereby underlining the overarching importance of customized medical care in handling and potentially reducing the effects of chronic diseases. For example, data from the National Library of Medicine, a government agency based in the U.S., indicated that by 2050, the number of U.S. citizens aged 50 or above with at least one chronic condition would rise to 142.66 million, as of January 2023. Consequently, the escalating incidences of chronic diseases are fueling the expansion of the Duchenne muscular dystrophy market.
What Are The Major Segments Within The Duchenne Muscular Dystrophy Market?
The duchenne muscular dystrophy market covered in this report is segmented –
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy
2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs
Pre-Book The Duchenne Muscular Dystrophy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Duchenne Muscular Dystrophy Market?
Industry leaders in the Duchenne muscular dystrophy market are pioneering technological innovations such as clinical trial design to amplify the productivity and success of drug development procedures, augment patient results, and hasten the approval of novel treatments. Clinical trial design entails the structuring and preparation of a clinical trial to determine the safety and efficiency of a new remedy and involves setting objectives, selecting participants, and delineating methods and analyses. For example, in March 2024, the Duchenne Regulatory Science Consortium of the US-based non-profit organization, Critical Path Institute (C-Path), launched the DMD Clinical Trial Simulator (CTS). This ground-breaking instrument, designed to maximize the blueprint of effectiveness studies for DMD treatments, features enhancements like advanced modelling of functional test results, ability to mimic various scenarios, improved efficiency in trial outlining, and universal access through the C-Path website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). It thus provides a crucial aid for research scientists and pharmaceutical businesses involved in DMD studies.
Who Are the Key Players in the Duchenne Muscular Dystrophy Market?
Major companies operating in the duchenne muscular dystrophy market include:
• Pfizer Inc.
• GlaxoSmithKline plc
• PerkinElmer Inc.
• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics Inc.
• PTC Therapeutics Inc.
• Asklepios BioPharmaceutical Inc.
• Catabasis Pharmaceuticals Inc.
• Wave Life Sciences Ltd.
• Bristol Myers Squibb Company
• BridgeBio Pharma Inc.
• Rocket Pharmaceuticals Inc.
• Italfarmaco SpA
• Solid Biosciences Inc.
• Avidity Biosciences Inc.
• Fulcrum Therapeutics Inc.
• Akashi Therapeutics Inc.
• WAVE Life Sciences Ltd.
• Capricor Therapeutics Inc.
• Santhera Pharmaceuticals Holding
• Armagen Technologies Inc.
• Dyne Therapeutics Inc.
• Benitec Biopharma Limited
• Edgewise Therapeutics Inc.
What Is The Most Dominant Region In The Duchenne Muscular Dystrophy Market?
North America was the largest region in the Duchenne muscular dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
